JANUARY 6, 2020 (KTAR News Photo/Griselda Zetino) PHOENIX — Arizona is projected to have one of the fastest growing rates of Alzheimer’s disease in the country over the next few years, and a clinical lab testing company in the Valley is trying to reverse that. Phoenix-based Sonora Quest Laboratories is working with a tech company called uMETHOD Health to collect patient data through a platform called RestoreU METHOD. The data…READ MORE

At the 2019 Alzheimer’s Association International Conference, July 14-18, in Los Angeles, California, uMETHOD Health shared results from an analysis that evaluated the implementation of a precision-medicine platform to create personalized, multidomain care plans for the treatment of dementia and mild Alzheimer disease. The algorithms analyze medication interactions and adverse drug reactions, such as drug-drug interactions, opioid usage, anticholinergic cognitive burden, and depression-inducing drugs, rate them using input from an open-source…READ MORE

Earlier this year the Center for Disease Control and Prevention (CDC) predicted that the burden of Alzheimer’s disease and related dementia (ADRD) in the United States is expected to double by 2060. It is predicted that Arizona has the second highest growth-rate of of Alzheimer’s disease, with cases expected to climb to 200,000 by 2025. ... Having multiple Alzheimer’s research centers & programs, some would say Arizona is at the…READ MORE

Alzheimer's disease (AD) is a progressive, neurodegenerative condition in which individuals exhibit memory loss, dementia, and impaired metabolism. Nearly all previous single-domain studies to treat AD have failed, likely because it is a complex disease with multiple underlying drivers contributing to risk, onset, and progression. Keine et al. explored the efficacy of a multidomain therapy approach based on the disease risk factor status specific to individuals with AD diagnosis or…READ MORE

Alzheimer's and Brain Awareness Month may have come to a close, but the important work of finding treatments continues. Despite drug development setbacks, several major announcements made during June will have a positive impact. On June 25th AARP announced a $60 million investment in the Dementia Defense Fund (DDF), an impact-driven venture capital fund that invests in innovative ideas related to dementia. With this donation, the DDF was able to…READ MORE